Cargando…

Association of Tocilizumab and Invasive Aspergillosis in Critically Ill Patients with Severe COVID-19 Pneumonia and Acute Respiratory Distress Syndrome

Coronavirus disease-2019 (COVID-19) causes severe pneumonia and acute respiratory distress syndrome. According to the current consensus, immunosuppressants, such as dexamethasone and anti-interleukin-6 receptor monoclonal antibodies, are therapeutic medications in the early stages of infection. Howe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Kuo-Lun, Chang, Chia-Yuan, Sung, Heng-You, Hu, Ting-Yu, Kuo, Li-Kuo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9026544/ https://www.ncbi.nlm.nih.gov/pubmed/35448570 http://dx.doi.org/10.3390/jof8040339

Ejemplares similares

Tocilizumab for severe COVID-19 pneumonia
por: Lipworth, Brian J, et al.
Publicado: (2020)

Tocilizumab: Invasive pulmonary aspergillosis following off-label use of tocilizumab for severe acute respiratory coronavirus-2 infection: case report
Publicado: (2021)

Risk Factors for Invasive Pulmonary Aspergillosis in Critically Ill Patients With Coronavirus Disease 2019-Induced Acute Respiratory Distress Syndrome
por: Chauvet, Paul, et al.
Publicado: (2020)

Dexamethasone/tocilizumab: Invasive pulmonary aspergillosis: case report
Publicado: (2021)

Severe ARDS in a critically ill influenza patient with invasive pulmonary aspergillosis
por: Pietsch, Urs, et al.
Publicado: (2016)

Recovery of COVID-19 acute respiratory distress syndrome with tocilizumab: successful outcome in two critically ill patients
por: Cala-García, Juan David, et al.
Publicado: (2020)

What’s new in invasive pulmonary aspergillosis in the critically ill
por: Koulenti, Despoina, et al.
Publicado: (2014)

Invasive aspergillosis in patients with severe COVID-19 pneumonia
por: Helleberg, Marie, et al.
Publicado: (2021)

PULMONARY ASPERGILLOSIS POST-TOCILIZUMAB TREATMENT IN A PATIENT WITH COVID-19 PNEUMONIA
por: GIDWANI, VIPUL, et al.
Publicado: (2022)

Invasive pulmonary aspergillosis in critically ill patients with severe COVID-19 pneumonia: Results from the prospective AspCOVID-19 study
por: Lahmer, Tobias, et al.
Publicado: (2021)

Microbiological diagnosis of pulmonary invasive aspergillosis in critically ill patients with severe SARS-CoV-2 pneumonia: a bronchoalveolar study
por: Estella, Ángel, et al.
Publicado: (2023)

A Comparison of Diagnostic Criteria for Invasive Pulmonary Aspergillosis in Critically Ill Patients
por: Liu, Rui-ting, et al.
Publicado: (2023)

Correction: Microbiological diagnosis of pulmonary invasive aspergillosis in critically ill patients with severe SARS-CoV-2 pneumonia: a bronchoalveolar study
por: Estella, Ángel, et al.
Publicado: (2023)

Management of invasive pulmonary aspergillosis in non-neutropenic critically ill patients
por: Trof, R. J., et al.
Publicado: (2007)

Invasive pulmonary aspergillosis in severe coronavirus disease 2019 pneumonia
por: Lahmer, T., et al.
Publicado: (2020)

Severe pediatric adenoviral pneumonia combined with invasive pulmonary aspergillosis
por: Huang, Shuihua, et al.
Publicado: (2023)

Tocilizumab: An Effective Therapy for Severely and Critically Ill COVID-19 Patients
por: Bhandari, Sudhir, et al.
Publicado: (2021)

Invasive pulmonary aspergillosis in critically ill patients with pneumonia due to COVID-19, influenza, and community-acquired pneumonia: A prospective observational study
por: Ali, Syed Ahsan, et al.
Publicado: (2022)

Incidence of invasive pulmonary aspergillosis among critically ill COVID-19 patients
por: Lamoth, Frederic, et al.
Publicado: (2020)

Prevalence of putative invasive pulmonary aspergillosis in critically ill patients with COVID-19
por: Alanio, Alexandre, et al.
Publicado: (2020)

Invasive pulmonary aspergillosis and candidiasis in a critically ill patient with COVID-19
por: Benedetti, María Fernanda, et al.
Publicado: (2022)

Risks of ventilator-associated pneumonia and invasive pulmonary aspergillosis in patients with viral acute respiratory distress syndrome related or not to Coronavirus 19 disease
por: Razazi, Keyvan, et al.
Publicado: (2020)

Comparison of Clinical Manifestation, Diagnosis, and Outcomes of Invasive Pulmonary Aspergillosis and Pulmonary Mucormycosis
por: Lin, Chun-Yu, et al.
Publicado: (2019)

Score-based prediction model for severe vitamin D deficiency in patients with critical illness: development and validation
por: Kuo, Yu-Ting, et al.
Publicado: (2022)

Tocilizumab for severe COVID-19 pneumonia
por: Mourad, Jean-Jacques, et al.
Publicado: (2020)

Tocilizumab for severe COVID-19 pneumonia
por: Piano, Salvatore, et al.
Publicado: (2020)

Disseminated enteroinvasive aspergillosis in a critically ill patient without severe immunocompromise
por: Fieber, Jennifer H., et al.
Publicado: (2013)

Correction to: Risks of ventilator-associated pneumonia and invasive pulmonary aspergillosis in patients with viral acute respiratory distress syndrome related or not to Coronavirus 19 disease
por: Razazi, Keyvan, et al.
Publicado: (2021)

Clinical features of invasive bronchial-pulmonary aspergillosis in critically ill patients with chronic obstructive respiratory diseases: a prospective study
por: He, Hangyong, et al.
Publicado: (2011)

Outcomes of Critically Ill Very Old Patients With Community-Acquired Pneumonia and Acute Respiratory Distress Syndrome
por: Cillóniz, Catia, et al.
Publicado: (2022)

Invasive aspergillosis in critically ill hematology patients: outcomes and prognostic factors associated with mortality
por: Burghi, G, et al.
Publicado: (2011)

Epidemiology of invasive aspergillosis in critically ill patients: clinical presentation, underlying conditions, and outcomes
por: Taccone, Fabio Silvio, et al.
Publicado: (2015)

Prevalence of Hospital-Acquired Pneumonia Among Patients With Severe to Critical COVID-19 Pneumonia Given Tocilizumab
por: Adre, Lorenzo Abednego B, et al.
Publicado: (2023)

Early Tocilizumab Dosing Is Associated With Improved Survival in Critically Ill Patients Infected With Severe Acute Respiratory Syndrome Coronavirus-2
por: Petrak, Russell M., et al.
Publicado: (2021)

563. Tocilizumab in the Treatment of Critical COVID-19 Pneumonia
por: Fisher, Matthew, et al.
Publicado: (2020)

Treatment of COVID-19 atypical pneumonia by early Tocilizumab administration in “non-critically-ill” patients on hemodialysis
por: Castellano, Giuseppe, et al.
Publicado: (2020)

Tocilizumab Use in a Chronic Hemodialysis Patient for the Management of COVID-19-Associated Pneumonia and Acute Respiratory Distress Syndrome
por: Gupta, Sudeendra, et al.
Publicado: (2020)

Tocilizumab: Invasive pulmonary aspergillosis and Escherichia coli infection due to off-label use: case report
Publicado: (2020)

Prevalence and outcome of invasive pulmonary aspergillosis in critically ill patients with liver cirrhosis: an observational study
por: Lahmer, Tobias, et al.
Publicado: (2019)

Impact of Invasive Pulmonary Aspergillosis in Critically Ill Surgical Patients with or without Solid Organ Transplantation
por: Dubler, Simon, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2fkbs5kda9f8opjs5d56pv2hi0